Sam W. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sam W. Lee has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Stuart A. Aaronson
Department of Medicine and ¶Cancer Biology Program, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine and Harvard Medical School, Boston, MA 02115; and §Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY 10029
2 shared publicationsAna M. Borras
From the ‡Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, Harvard Medical School, Boston, Massachusetts 02115 and the ‖Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029
1 shared publicationC L Reimer
1 shared publicationCorinne L. Reimer
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
1 shared publicationD B Campbell
1 shared publicationDavid R Rigney
1 shared publication
Latest Publications
- Open Access
- 11 July 2000
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (15) , 8302-8305
Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53
The p53 tumor suppressor gene can inhibit proliferation transiently, induce permanent cell-cycle arrest/senescence, or cause apoptosis depending on the cellular context. The mitogen-activated protein kinase (MAPK) cascade is known to play a crucial role in cell proliferation and differentiation. Moreover, the duration and intensity of MAPK activation can profoundly influence the biological response observed. We demonstrated that a sustained activation of MAPK cascade could be induced by wild-type p53 expression but not by p21 Waf1/Cip1 . Furthermore, exposure of normal cells to DNA-damaging agents induced MAPK activation in a p53 -dependent manner. Tumor-derived p53 mutants defective in DNA binding failed to activate MAPK, implying that p53 transcriptional activity is essential for this function. Finally, activation of MAPK by p53 was inhibited by expression of dominant-negative Ras (N17Ras) and Raf1 mutants, indicating that MAPK activation by p53 is mediated at a level upstream of Ras. All of these findings establish a biochemical link between p53 signaling and the Ras/Raf/MAPK cascade.
- 11 July 2000
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (15) , 8302-8305
Open AccessSustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53
The p53 tumor suppressor gene can inhibit proliferation transiently, induce permanent cell-cycle arrest/senescence, or cause apoptosis depending on the cellular context. The mitogen-activated protein kinase (MAPK) cascade is known to play a crucial role in cell proliferation and differentiation. Moreover, the duration and intensity of MAPK activation can profoundly influence the biological response observed. We demonstrated that a sustained activation of MAPK cascade could be induced by wild-type p53 expression but not by p21 Waf1/Cip1 . Furthermore, exposure of normal cells to DNA-damaging agents induced MAPK activation in a p53 -dependent manner. Tumor-derived p53 mutants defective in DNA binding failed to activate MAPK, implying that p53 transcriptional activity is essential for this function. Finally, activation of MAPK by p53 was inhibited by expression of dominant-negative Ras (N17Ras) and Raf1 mutants, indicating that MAPK activation by p53 is mediated at a level upstream of Ras. All of these findings establish a biochemical link between p53 signaling and the Ras/Raf/MAPK cascade.
- Open Access
- 1 April 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (16) , 11022-11029
Altered Regulation of Cyclin G in Human Breast Cancer and Its Specific Localization at Replication Foci in Response to DNA Damage in p53+/+ Cells
- 1 April 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (16) , 11022-11029
Open AccessAltered Regulation of Cyclin G in Human Breast Cancer and Its Specific Localization at Replication Foci in Response to DNA Damage in p53+/+ Cells
- Open Access
- 1 June 1998
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 19 (6) , 1157-1159
H-cadherin expression inhibits in vitro invasiveness and tumor formation in vivo
H-cadherin is a newly characterized cadherin molecule whose expression is decreased in a variety of human carcinoma cells, suggesting that it may play a role in maintaining normal cellular phenotype. To investigate how re-expression of H-cadherin could influence the malignant phenotype of human breast carcinoma cells in vivo, we transfected both control and H-cadherin expression vectors into human breast cancer cells (MDAMB435), which do not express H-cadherin constitutively. We found that invasiveness of these cells could be prevented by transfection with H-cadherin. We also compared the ability of control- and H-cadherin-transfected cells to induce subcutaneous tumors after injection into mammary fat pads of nude mice. Our results show that H-cadherin transfection produced a marked inhibition of tumor growth and modified the morphology of tumor cells: tumors from mice injected with control cells were significantly larger and contained larger cells having a higher degree of pleomorphism than those of tumors generated from carcinoma cells expressing H-cadherin. Altogether, these results indicate that H-cadherin expression antagonizes tumor growth in nude mice, presumably by enhancing cell-cell association in a tissue environment. These findings strongly suggest that H-cadherin could provide a possible target for corrective gene therapy against breast cancer.
- 1 June 1998
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 19 (6) , 1157-1159
Open AccessH-cadherin expression inhibits in vitro invasiveness and tumor formation in vivo
H-cadherin is a newly characterized cadherin molecule whose expression is decreased in a variety of human carcinoma cells, suggesting that it may play a role in maintaining normal cellular phenotype. To investigate how re-expression of H-cadherin could influence the malignant phenotype of human breast carcinoma cells in vivo, we transfected both control and H-cadherin expression vectors into human breast cancer cells (MDAMB435), which do not express H-cadherin constitutively. We found that invasiveness of these cells could be prevented by transfection with H-cadherin. We also compared the ability of control- and H-cadherin-transfected cells to induce subcutaneous tumors after injection into mammary fat pads of nude mice. Our results show that H-cadherin transfection produced a marked inhibition of tumor growth and modified the morphology of tumor cells: tumors from mice injected with control cells were significantly larger and contained larger cells having a higher degree of pleomorphism than those of tumors generated from carcinoma cells expressing H-cadherin. Altogether, these results indicate that H-cadherin expression antagonizes tumor growth in nude mice, presumably by enhancing cell-cell association in a tissue environment. These findings strongly suggest that H-cadherin could provide a possible target for corrective gene therapy against breast cancer.
- 1 February 1997
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 373 (2) , 179-184
Downregulation of DNA topoisomerase I in old versus young human diploid fibroblasts
- 1 February 1997
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 373 (2) , 179-184
Downregulation of DNA topoisomerase I in old versus young human diploid fibroblasts